Grifols, S.A. G0FB.F Stock
Grifols, S.A. Price Chart
Grifols, S.A. G0FB.F Financial and Trading Overview
| Grifols, S.A. stock price | 6 EUR |
| Previous Close | 9.05 EUR |
| Open | 9.1 EUR |
| Bid | 0 EUR x 31000 |
| Ask | 0 EUR x 30000 |
| Day's Range | 9.1 - 9.1 EUR |
| 52 Week Range | 5.85 - 9.75 EUR |
| Volume | 15 EUR |
| Avg. Volume | 14 EUR |
| Market Cap | 8.12B EUR |
| Beta (5Y Monthly) | 0.44436 |
| PE Ratio (TTM) | 53.529415 |
| EPS (TTM) | 0.09 EUR |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | June 3, 2021 |
| 1y Target Est | 11.91 EUR |
G0FB.F Valuation Measures
| Enterprise Value | 24.2B EUR |
| Trailing P/E | 53.529415 |
| Forward P/E | 16.851852 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 1.2526295 |
| Price/Book (mrq) | 2.1072133 |
| Enterprise Value/Revenue | 3.735 |
| Enterprise Value/EBITDA | 26.274 |
Trading Information
Grifols, S.A. Stock Price History
| Beta (5Y Monthly) | 0.44436 |
| 52-Week Change | N/A |
| S&P500 52-Week Change | N/A |
| 52 Week High | 9.75 EUR |
| 52 Week Low | 5.85 EUR |
| 50-Day Moving Average | 8.6 EUR |
| 200-Day Moving Average | 7.85 EUR |
G0FB.F Share Statistics
| Avg. Volume (3 month) | 14 EUR |
| Avg. Daily Volume (10-Days) | 1 EUR |
| Shares Outstanding | 678.41M |
| Float | 831.7M |
| Short Ratio | N/A |
| % Held by Insiders | 0% |
| % Held by Institutions | 46.27% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 2:1 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | June 30, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0.13% |
| Operating Margin (ttm) | 9.46% |
| Gross Margin | 35.99% |
| EBITDA Margin | 14.21% |
Management Effectiveness
| Return on Assets (ttm) | 1.80% |
| Return on Equity (ttm) | 1.24% |
Income Statement
| Revenue (ttm) | 6.48B EUR |
| Revenue Per Share (ttm) | 4.7 EUR |
| Quarterly Revenue Growth (yoy) | 7.79% |
| Gross Profit (ttm) | 2.23B EUR |
| EBITDA | 921.07M EUR |
| Net Income Avi to Common (ttm) | 8.41M EUR |
| Diluted EPS (ttm) | 0.17 |
| Quarterly Earnings Growth (yoy) | -42.39% |
Balance Sheet
| Total Cash (mrq) | 541.1M EUR |
| Total Cash Per Share (mrq) | 0.4 EUR |
| Total Debt (mrq) | 10.03B EUR |
| Total Debt/Equity (mrq) | 121.94 EUR |
| Current Ratio (mrq) | 2.56 |
| Book Value Per Share (mrq) | 4.3185 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -146132992 EUR |
| Levered Free Cash Flow (ttm) | -194460000 EUR |
Profile of Grifols, S.A.
| Country | Germany |
| State | N/A |
| City | Barcelona |
| Address | Avinguda de la Generalitat, 152 |
| ZIP | 08174 |
| Phone | 34 93 571 05 00 |
| Website | https://www.grifols.com |
| Industry | Drug Manufacturers-General |
| Sector(s) | Healthcare |
| Full Time Employees | 23631 |
Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada and internationally. The Biopharma segment provides plasma derivatives products, including Gamunex/Gamunex-C Immune Globulin Injection, Flebogamma Immune Globulin Intravenous, Xembify Immune Globulin Subcutaneous solution, HyperRAB Rabies Immune Globulin, Prolastin/Prolastin-C/Prolastin-C Liquid/Prolasplan/Prolastina/Pulmolast/Lynspad Alpha 1-Proteinase Inhibitor, Fanhdi and Alphanate, Antihemophilic Factor/von Willebrand factor Complex, Koate-DVI Antihemophilic Factor, Albutein/Albutein Flexbag/ Human Albumin Grifols/Plasbumin Albumin, and Vistaseal/Veraseal; and Tavlesse, a non-plasma derivative medicinal product. The Diagnostic segment offers transfusion medicine, which includes Procleix Panther systems/Procleix Panther with Automation Ready technology, Automated NAT blood screening systems, assays, software, WADiana/Erytra/Erytra Eflexys analyzers, BLOODchip ID/IDCore/IDHPA/IDRHD/IDCORE/BIDS, and antigens; and clinical and diagnostics products, such as Promonitor and Alpha1D. The Bio Supplies segment provides human biological materials for life sciences research and the development and manufacturing of pharmaceutical and diagnostic products. The Others segment offers healthcare solutions, which provides services and manufactures products, including parenteral solutions, robotics, and software used by hospitals, blood banks, plasma collection centers and other healthcare systems. The company's products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. Grifols, S.A. has collaboration agreements with Canadian Blood Services for the processing of other plasma-derived products, and with GIANT and GigaGen to develop recombinant polyclonal immunoglobulin therapies. The company was founded in 1940 and is headquartered in Barcelona, Spain.
Q&A For Grifols, S.A. Stock
What is a current G0FB.F stock price?
Grifols, S.A. G0FB.F stock price today per share is 6 EUR.
How to purchase Grifols, S.A. stock?
You can buy G0FB.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Grifols, S.A.?
The stock symbol or ticker of Grifols, S.A. is G0FB.F.
Which industry does the Grifols, S.A. company belong to?
The Grifols, S.A. industry is Drug Manufacturers-General.
How many shares does Grifols, S.A. have in circulation?
The max supply of Grifols, S.A. shares is 865.13M.
What is Grifols, S.A. Price to Earnings Ratio (PE Ratio)?
Grifols, S.A. PE Ratio is 66.66666400 now.
What was Grifols, S.A. earnings per share over the trailing 12 months (TTM)?
Grifols, S.A. EPS is 0.09 EUR over the trailing 12 months.
Which sector does the Grifols, S.A. company belong to?
The Grifols, S.A. sector is Healthcare.